IAPO
Intematlonal AllIan￿ of
Patients. Organizations
Chwty reglstratim n￿nber{EnSIand and Wales>.1155577
Intemational Alliance of Patients, Organizations
(Incorporated as a Company Limited by Guarantee
and not having a Share Capital)
Annual Report and Financial Statements
forthe Year Ended in December 2025

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Contents
Reference and Administrative Details of The Charity, Its Trustees and Advisers
Trustees, Report for the Year Ended 31 December 2025
Independent Auditor's Report to the Members of International Alliance of Patients,
Organizations forthe Year Ended 31st December 2025
35
Statement of Financial Activities Ilncorporatfng an Income and Expendlture Attountl for the
Year Ended 31 December 2025
39
Balance Sheet as at 31 December 2025
40
Notes to the Financial Statement5 for the Year Ended 31 December 2025
41

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Reference and Administrative Detsils of the Charityj Its Trustees and Adviser5
Company number
08495711 (England and Wales)
Charlty number
1155577 (England and Wales)
Registered office
International Alliance of Patients, Organizations
Canopi, 82 Tanner Street, London, SEI 3GN, UK
Governlng Board members
IBoard of Trustees)
Profe550r Lara Claire Bloom
Orajitt Bumrung5kulswat
Flavia Kyomukama
Paul Albert Sumat Mendoza
Fernanda Souza de Carvalho
Agron Bytyqi
Dr. Ratna Devi
Vasiliki-Rafaela Vakouftsi
Waèl Kamel Ali Ali Mazrouh Iloined 15 Nov 20251
Chief Exècutive
Daniela Espindula Mothci
Bankers
Natwest Bank PIC
PO Box 12258
I Princes Street
LONDON
EC2R 8BP
Independent auditor
Knox Cropper LLP
65 LÈ8dÈnhall StrÈet
London
EC3A 2AD
Website

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
The directors, who are also the trustee5 of the charity, are pleased to present their report together with
the financial statements of the charity for the year ended 31 December 2025 which are also prepared to
meet the requirements for a directors, report and accounts for Companies Act purposes.
IAPO Trading Limited Icompany number 088631901 wa5 dormant and wa5 di55olved in July 2024.
The trustees have complied with the duty to have due regard to guidance issued by the Charitv
Commission and have adopted the Statement of Recommended Practice for charities ISORPI IFRS 102
second edition effective I january 20191.
Aims and objectives of the organisation
The International Alliancè of Patiènts, Organizations IIAPOI is a global alliance of patiènt organisations
working Bcross all disease areas, region5 and populations tg advance people-centred healthcare. We
mobilise and 5UPPOrt patient organisations worldwide, strengthening their capacity to represent patient5,
families and carers and to play an active role in shaping health policy, research and healthcare systems.
By connecting patient organisations, amplifying their collective voice and providing opportunities for
collaboration, learning and advocacy, IAPO helps ensure that health systems are shaped by the needs.
preferences and lived experiences of the people and communities they serve. Through our global network
and engagement with international health insritutions, we work to foster patient-centred healthcare and
improve health outcomes.
IAPO wès first established in 1999 in the Netherlands as a Dutth Stichting and subsequently deregistered,
registering in England and Wales a5 3 company limited by guarantee on 19 April 2013 and 3 charity on 30
January 2014. IAPO has a membership of nearly 300 organisations across 74 countries covering 52 disease
groups. IAPO is a Non-state Actor in official relations with the World Health Organization (WHO) and has a
consultative status with the United Nations Economic and Social Council. IAPO has a memorandum of
understanding with a variety of organisations including the International Council of Nurses IICNI,
International Hospital Federation IIHFI, International Pharmaceutical Federation IFIPI, World Medical
sociation IWMAI.

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
IAPO'S vlslon and mlsslon
IAPO'S vlslon and mission was updated in 2024 following the organisation's 2
h Anniv
VTs¥on
A workl there heath
systemsare sh4)ed by
UnPaUFy noeds arKI
Mission
Md)lise 8nd pthnt
erganisat1tinsart￿m￿ ttr
v￿d,emrX?werfrfj them to
play ah¥li¥è rde ￿(*¢110n
maing proC*ssesslw￿n91
a￿1
In 2025, IAPO continued its mission to help build people-centred healthcare worldwide by:
Empowering patients. organisations. maximizing their impact through capacity building
Advocating internationally with a strong patients. voice on relevant èspects of healthcare policy,
with the aim of influencing international, regional and national health agendas and policies
Building cross-sèctor alliantes and working collaborativèly with like-mindèd medical and health
professionals, policy makers, academics, researchers and industry representatives
IAPO'S artivities include:
Advocacy at global level on relevant aspects of healthcare policy to influence international health
agendas and policies
Providing membership services, including capacity building and shared learning, to its members,
who 3re patient-led organisations 3cr055 the world
Empowering its members to undertake their own advocacy at regional and national meetings
Providing opportunities for stakeholders from across the health sector to meet and work together
to advance patient involvement in health services and decision-making
Research on emerging areas of interest to patients, organisations and to underpin the evidence
base for showing the importance of patient Involvement to public health.

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Structure
The organisation is a charitable company limited by guarantee, incorporated on 19 April 2013 and
registered as a charity on 31 january 2014. The company was established articles of association which
deline the objects 2nd powers of the company and its governante arrangements. In the event of the
ompany being wound up member5 are required to contribute an amount not exceeding £1.
All assets and liabilities from the International Alliance of Patients Organizations and its predecessor
not-for-profit structure registered in the Netherlands, were transferred to the new UK incorporated charitv
on l February 2014. IAPO Nethèrlands was Ivoluntarilyl dissolved from thÈ Netherlands TradÈ RÈgistÈr
with effert from 31 May 2015, executed on 21 October 2015.
Appointment and induction of Governing Board
Every member of the IAPO Governing Board is elected by IAPO'S members. through a process defined in
the arhcles of Association b -laws and election code of conduct. Every year, in advance of the annual
general meeting IAGMI, the number of vacancies on the Board 15 notified to all members, who may then
nominate someone from their organisations la Board member or senior staff member) to IAPO'S
GDverning Board. The full list of nominees is sent to all members in advance of the AGM- members mav
vote by post or proxy or in person at the AGM.
Governing Board members serve for a maximum of two terms subject to the retirement by rotation clause,.
once their term of service is complete. they or anyone from their organisation cannot be re-elected to the
Board for at least a year. All new members of the Board receive induction including core information
about the work and history of the organisation, and conversations with the Chief Executive Officer and the
Chair.
All Governing Board members sign a code of conduct when they are appointed to the Board. All stsff and
Governing Board members are required to declare any relevant conflict of interests or conflict of loyalties
at Èvery Board mÈeting, or betwÈÈn meetings if applicable. Thè Governing Board has no beneficial intèrest
in the charitable company or it5 trading 5ub5idiary. No Governing Board member receives any
remuneration, but some receive reimbursement for essential travel or similar expen5e5.

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Governance
The International Alliance of Patr'ents. Organizations has a Board of Trustees and Directors overseeing its
governance and direction, supported by a secretariat headed by the Chief Executive Officer.
Board of TrusteeslDirertor5
Name
Professor Lara Bloom
I Position
Chair
Country
United
Kingdom
Philippines
Thailand
Dates
Mr. Paul Albert Mendoza
Mrs. Orajitt Bumrungskulswat
Secretary
Board
Member
Ms. Flavia Kyomukama
Treasurer
Ms. Fernanda SoLJza de Carvalho Board
Member
Board
Member
Board
MÈmbèr
B03rd
Member
Board
Member
Uganda
Brazil
Mr. Agron Bytyqi
K050VO
Dr. Ratna Devi
India
Ms. Va5iliki-Rafael3 VakoLJftsi
Greece
Dr. Wael Kamel Ali Ali Mazrouh
Egypt
Since 15 Nov 2025
*auaiJpd IPqOIy '

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Public benefit
The Governing Board tonlirm5 that they have considered the guidance contained in the Charity
Commission's general guidance on public guidance when reviewing the charity's aims and objectives. They
consider that the activities carried out, summarised in the Achievements and Performance section of this
report, provide benefit to the public.
IAPO'S objectives are the promotion of the relief of sickness and the preservation and protection of health
for the public benefit. IAPO pursues this through fostering parient-centred healthcare worldwide and, in
parbcular, by developing the capacity of patient5, or8anisations.
In sethng our objectives 2nd planning our activities trustees have given consideration to the Charitv
Commission's general guidance on public benefit IPBI, PB2 and P831 and have taken these into account in
making all decision5. We have not departed from the guidance in 2025.
IAPO'S services are open to all people and our membership reflects a diverse group of patients,
organisations representing patients with communicable and non-communicable diseases, including
patients with diseases that are stigmatised in many societies.
IAPO had 278 members comprising umbrella groups and single organisation5 in 2025 who directly
represented views of over I million patients in 72 countries across 54 disease areas. The service5 the
charity provides are designed to build the capacity of patients, organisations, allowing them to better assist
the needs of patients and Ca￿rS land their own member patient organisations in some cases) from across
the world.
Access to IAPO'S website is freely available to the public. Currently it is in English, with some sections in
Spanish. The website Contains a wide range of information on IAPO'S activities and on patient-centred
healthcare. which is of benelit to the public. particularly those who wish to set up local patients,
org3nisations.
By improving access to information, training and other capacity building programmes for patients and their
representative organisations, IAPO improves access to healthcare itself. By raising awareness and through
capacity building and education, we increase access to acceptable services that respect patients,
preferences, values, rights and needs.
IAPO has a wealth of evidence, gained from patient5, organisation5 worldwide, which demonstrates that
patient involvement in patient5, care leads to better health outcomes and lower costs for the whole of
society. The charity works with patients. organisations that are not for profit and non-governmental
organisations who demonstrate commitment to improving p3tient-centred healthc3re which 15 reflected in
the charity's membership criteria.

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Chair's Report for the Financial Year 1st January to 31st December 2025
If 2024 was 3 year of transition 2nd renewal for IAPO- laying h.rm foundations and sethng a clear strategic
direction
then 2025 was the year in which we put that strategy into action. Building on the FACE
framework launched in 2024. IAPO moved with purpose and confidence. translating our renewed vision
into tangible impact for the global patient organisation community. Across all four pillars
Facilitation.
Advocacy, Collaboration and Empowerment- 2025 was defined by delivery, deepened partnerships, and a
growing recognition of IAPO'5 voice on the world stage.
For the first time, our Global Patients Congress was held in Asia, bringing together MO￿ than 200
parhcipant5 in Manila, Philippines, and online. The Congress highlighted the power of patients, voices and
lived experience in shaping health systems worldwide. A key outcome of the Congress was the launch of
the Global Patient Charter on Social Participation, a practical framework to help patient organisations
engage governments and advance meanineful partr'cipation in health decision-making.
Our influence within global health institutions also continued to grow. IAPO'S status as a Non-state Actor in
official relations with the World Health Organization IWHOI was renewed. 2nd a new three-year
Collaboration Plan w35 approved. Through our engagement at the World Health A55embly and other
high-level global forums, we ensLJred that patient persP@ctive5 informed discussions on patient safety,
quality of care, Social participation and universal health coverage.
Partnership rèmained central to our work. Together with fivè leading global hèalth organis8tions, we
adopted the healthcare Sector's kn.rst joint ethic31 principle on the responsible use of health data,
technology and artificial intelligence through the International Consensus Framework for Ethical
Collaboration. We also continued to support the ratification of the African Medicines Agency Treaty,
helping advance efforts to strengthen access to safe and effective medicines across Africa.
At the heart of these achievements are our members. Through increased opportunities to engage in our
programmes and initiatives, we continued to connect, support and amplify patient organisations around
the world, strengthening our collective impact and advancing patient-centred health￿re.
In 2025. we made 3 number of strategic investments to strengthen IAPO'S organisation31 capacity,
intluding thè rècruitment of 3 Communications officer 8nd èngagement with specialist consultancies and
professional services to further enhance our sustainability, operations and governance.
These investments were an intentionzl and forward-looking decision, enabling us to deliver the ambitious
programme of work outlined in thi5 report while building the foundation5 for future growth. Supported bv
strong cash reserves, we were well-positioned to invest in the organi5ation's long-term resilience and
impact.

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
The board remains confident that these decisions will help position IAPO for its next phase of
development, ensuring we continue to strengthen our voice, expand our reach. and deliver value for our
members and the wider patient organisation community.
Building on our progress in 2025. we move forward with momentum. conlidence and a clear sense of
purpose, leaving us well placed to continue advancing people-centred healthcare and to ensure that the
voices of patients and people with lived experiente remain at the heart of Èlobal health.
None of this would have been possible without the dedication of our member organisations. the
commitment of our staff and leadership team. and the generosity of our partners and funders. On behalf
of the governing board, l extend my sincere gratitude to all of them.
Professor Lara Bloom
Chalr of IAPO Governlng Board
io

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Achievements and Performance
The International Alliance of Patients. Organizations- IAPO is a pioneer alliance representing the global
voice of alrn05t 300 patient org3nisahons acr055 all disease areas and from all regions of the world. We
were established in 1999 to co113borate on common agendas for the patient organisation community and
address challenges that transcend national borders. In 2025, IAPO continued its journey of collaboration,
advocacy and innovation to empower the patient organisation community and advance people-centred
healthcare globallv.
Since 2007, IAPO has held the status of Non-state Actor in official relations with the World Health
Organliatlon. This status is granted to entities that are international in membership and scope and
tontribute signifitsntly to the advancement of public health. IAPO also has a speclal consultative status
with thè United Nations Etanomit and Sotial Countil since 2014, allowing us to actively engage with the
Council, the United Nations Secretariat, and across programmes, fund5 and agencies in several ways.
The FACE Framework
This report presents our 2025 highlights organised around the major initiatives and workstreams that
defined OLJr year. Each is mapped to IAPO'S im
act strate
the FACE framework (Facilitation, Advotaty,
Collaboration and Empowerment), launched during our 25, Anniv
n in 2024.
Facilitation
Advocacy
Collaborntlon
, Representhg the
t&reEt5
tient orfjar¥qotions
p￿IdInq impa¢tfyl 8Dd
ryanisatl¢)ns Flc*ally lo 1 5U8t•lnatle partn¢F$hip5
raise 4*8￿ne$S end
inflvpn¢e p￿¢V
stakehelr*erallarrt¢s to
deers￿￿-m8*1rtg thJl
l advarKe •uend8s forthe
rol*t Ihv and
91ob¥ patienl
prelerence5 Ot the
0194ni$ation corrmuntty.
vmmuniti¥s Ihey
￿￿pP￿rtingfhe
dovuknpm4nl g(polie
Or￿n1$￿tIonS. C8p3bilti
and l¢sl¥rfng 4
c¢mmufjity tor utowt
dnd Goll*DratiDn.
through re$￿Irces,
¢¥gnlb, Itaining 4tKI
I￿.￿.an9￿nfj knowledg
btssl pr¢L11¢95, and
¥ative 8ppr08che$ 10
VonG¢ glot>al health
li

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Bècause our work is deeply interconnected, most initiativès advance more than one pillar of the FACE
framework at once. The table below mBp5 the year's work onto the four pillar5 Ht a 8lance.
What it meant in 2025
Learn about it in section
Facllitatlon
Representing
members,. exchanging
knowledge and
evidence
2. Engagement with the WHO and the multilateral
system
5. Research and evidence
6. Strengthening our membership and community
Advocacy
Influencing policy and
decision-making
l. Universal Health CoveraEe and Social Participation
2. Engagement with the WHO and the multilateral
system
3. African Medicines Agency Treaty Alliance IAMATAI
Collaboratton
Building partnerships
and alliances
2. Engagement with the WHO and the multilateral
system
3. African Medicines Agency Treaty Alliance IAMATAI
4. Personalised Cancer Care Alliance IPCCAI
7. Wider partnerships and sector collaboration
Empowerment
Building mèmber
capability and
community
l. UnivÈrs81 HÈ8lth CovÈrage and Social Partitipation
4. Personalised Cancer Care Alliance IPCCAI
6. Strengthening our membership and community
Thgc•naboYakn T￿* ollhè
91obulpaiiortoryunltaiian
rvmTroythyln4Jdvunelng
soclalportldpgtlonl
un1v•rsaih￿1th<oYgl

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
l. Universal Health Coverage and Social Participation
Advancing.. Advocucy . Empowerment. Fucilitation
Universal health coverage IUHCI and social participarion sit at the centre of IAPO'S mission. In 2025 thev
were the through-line connecting several of our flagship initiatives- from the launch ol the Global Patient
Charter on Social Participation to the continued growth of the UHC Compass.
Global Pauent Charter on So¢lal Partl¢lpaUon
A landmark initiative launched at IAPO'S Ilth Global Patients Congress in Manila in November 2025, the
Global Patient Charter on Social Partici
ation 15 a practical advocacy tool designed to help patient
organisations in engaging governments and promoting locally rooted and context-sensitive social
participation. It was developed as part of IAPO'S efforts to promote social parkncipation in line with the
World Health Assembly resolution on social participation for universal health Coverage. health and
well-being adopted in 2024, and offers concrete benchmarks for what meaningful social participation
shoLJld look like.
It was co-created over several months through the collective input of more than 35 IAPO members and an
advi50ry groLJP of over 20 health expert5, including WHO representatives, three 515ter organi53tions IRare
Diseases International, the European Patient5, Forum, and Patient Movement Cataly5tl and partners such
as NCD Alliance, UHC2030, CSEM, and the Lancet Commission on People-centred Healthcare. The task
force met throughout 2025 to provide valuable feedback on drafts of the Charter. and rounds of
consultations with key targeted groups also took place.
In October 2025, the WHO Civil Society Commission offered IAPO the opportunity to present the draft
Charter to its members across the wider civil society community and Eather their feedback.
Following the launch in November, the Charter was disseminated across different regions. with very
encouraging reports about its uptake.
World Health Organization UHC2030 Task Force
Established in 2022, the UHC2030 Task Force leverages its expertise and networks to sustain momentum
for the implementation of universal health coverage and advises the UHC2030 Secretariat on
accountability for results.
In 2025 IAPO was invited to join the steering committee of the task force and serve as a representative of
the patient organis8tion community. Thè task force convenès rèpresentativès from various conthtuencies
to ensure accountability for, and drive the implementation of, the UHC Political Declaration.
13

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
The work focuses on the development of thè new COLJntry profile dashboards for the 'From Commitment
to Action.. A Global UHC Action Tracker Report,, as well a5 on elevating the key findin85 and
recommendations to policymakers once the data analysis is concluded.
UHC Compass
Theu
Q£omuass was developed by the Global Patient Think Tank IGPTTI which was convened by Roche.
IAPO was one of the GPft members and chosen to tarry on the work of the UHC Compass. In 2025 we
continued developing the tool bzsed on user feedback and exp3nded its reach and impact through
engagement with key stakeholders, networks and events. We started the digitali5ation of the Compass into
an online platform with an integrated feedback survev.
IAPO delivered four se55ion5 on the UHC Compass for patient organisations attending the regional
International Experience Exchange with Patient Organisations IIEEPOI workshops in Latin America, Africa,
Eastern Mediterranean and the Asia-Pacilic workshop.

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Patlent Solldarlty Day
Patient Solidari
Da
PSD
takes place every December. when patients and people with lived experience
around the world unite to spotlight a key issue affechng our global patient organisation community. Patient
Solid8rity Day inspires attion through soci31 mÉdia campaigns, lotal Èvents, and global convèrsations- all
aimed at puthn8 patients at the heart of healthc3re.
We celebrated PSD on 3 December 2025 under the theme 'The Global Patient Charter on Social
Parhcipation,, championing the importance of meaningfLJI engagement of patients and people with lived
experience in health governance, following the launch of IAPO'S Global Patient Charter on Social
Participation. To mark the day, we encouraged all to endorse the Charter, and created a variety of
messaÉes and social media assets for members to share with their networks, amplifying voices and impact.
Representation on UHC and social participation
+ IAPO co-hosted the 2
with ￿Em for UHC2030 and other civil
society organisations, in a session titled 'A youth-parliamentarian dialogue on partnering for
progress towards affordable health for all,.
+ IAPO spoke at the Patient En
ement O
the plenary session and in one of the co-creation sessions.
+ IAPO spoke at the
mFr
(Frontiers of Health) in Brazil, at the opening
ceremony 'Collaboration in Health.. Building Health Public Policies with a People-centred Focus,
and the session 'Patients' Rights and UHC,.
enF
PE
in Italy, about social participation at
2. Engagement with the World Health Organization and the multilateral system
Advancing.. Advocacy. Collaboration . Facilitation
As a Non-state Actor in official ￿latiOnS with the World Health Organization IWHOI, IAPO works closelv
with the organization acr055 adv0￿C¥, collaboration and technical engagement. In 2025, the IAp¢>WHO
Collaboration Plan1202>20271 wa5 reviewed by the WHO Executive Board and approved at its 156th
session in February, and our Non-state Actor status was successfully renewed until the next triennial
review.
Patient Safety and Quality of Care
part of our collaboration plan with the WHO IAPO spoke at the Vll Global Ministerial Summit on
EatiollL&th134 April. Philippinesl. in the opening session on the role of patients and patient
organisations in improving patient safety and supporting the implementation of the Global Patient Safety
Action Plan 2021-2030.
15

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
IAPO also produced the narrative review 'Putient Safttyfrom the Patient Perspective.. Unmet Needs
and Opportunitiesfor Engagement., by analysing existing literature and available evidence, and
emphasising its alignment with the Global Patient Safety Action Plan 2021-2030.
A WHO-led initiative observed yearly on 17 September, World Patient Safet Da
calls for global
501idarity and concerted action by all countries and international partners to improve patient safety. The
day brings together patients, families, caregivers, communities, health workers, health care leaders and
policy-makers to show their commitment to patient safety and quality of care.
WPSD
The activities undertaken to mark WPSD 2025 are part of the IAPO-WHO Collaboration Plan12025-20271.
Some of the highlights include..
+ IAPO jointly hosted a webinar with the Patients for Patient Safety Observatory on Tuesday.
16 September. titled "En
in
Families and Communities Protectin
Eve
Newborn
Eve
Child" The interactive session brought together leading experts from the World
Health Organization, UNICEF Montenegro, Joint Commi55ion International and ICAN
Ilnternational Children's Advi50ry Network) for a crucial conversation about protecting our
most vulnerable patients. The session was recorded and osted on IAPO'S YouTube
channel.
+ IAPO also took part in the WHO'S global webinar, S(7ft carefor every newborn anLI every
chilLI', which took place virtually on 8 September 2025.
+ IAPO tailored a
uide to su
ani5ation5 in marking WPSD, including kev
information about the campaign and social media captions for online use.
ort atient or
+ IAPO'S full re
ort of WPSD activities can be found here.
Multilateral Statements
A5 a Non-state Actor, IAPO is entitled to lead and join individual and constituency statements during
Executive Board meetings and World Health Assemblies. At the WHO 156th Executive Board. held 3-11
February 2025. IAPO delivered an individual statement along with Fi
ht the Fakes Alliance on Agenda item
12.. Substandard and Falsified Medical Products. We also joined six constituency statements, as follows..
+ Two statements on universal health coverage.. one on the World Health Assembl Resolution
Int
rn
nal and the other on Int
rn
in
vi
mm
ni
WHAR
ni
Medical Ima
in
Ca
acit b the World Federation of Nuclear Medicine and Biol
16

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
+ Two statements on health emergencies.. onè led b Global Hèalth Council and the othèr b
he International Fe
fph
rm
eutical Manufacturer5 and Associati
IIFPMAI.
+ A statement on
I h led by the World Heart Federation.
+ A statement on the involvement of Non-state Artors
NSA5
in WHO'5
overnin
by the Global Health Council.
bodies led
The
took place on 19-27 May 2025. During the event, IAPO worked
to amplify the voice of patients and people with lived experience across multiple global health discussions
by delivering and joining several statements on key agenda items, such as..
+ One individual statement delivered by IAPO on sub
behalf of the African Medicines Agency Treaty Alliance IAMATAI, of which IAPO is founding
member and holds the secretariat, and as part of The Fight the Fakes Alliance.
son
17

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
+ Two statements on univers31 health coverage, one led by NCD Alliance and one led by Save
the Children.
+ One on the Follow-up to the Political Declaration of the Third High-Level Meeting on NCDS. led
by the International Society of Nephrology IISNI.
+ One on climate change and health, led by the World Heart Federation IWHFI.
During 2025, IAPO actively supported two draft resolution5 that were recommended for adoption at the
78th World Health Assembly in May.. one on rare diseases through our engagement in the Coalition in
Support of the Resolution on Rare Diseases led by Rare Diseases International, and one on skin diseases.
We also 5UPPOrted another draft resolution on
which wa5 equally
recommended for adoption atthe WHA78.
In response to the recent U.S. decision5 affecting global health, IAPO issued a statement highlighting the
impact on patient5 and patient organisations, reaffirming our support to the WHO and calling for global
solidarity.
WHA78 side events
DLJring WHA78, IAPO jointly hosted four side events..
+ With the Civil Socie
ement Mechanism for UHC2030
on 19 May. the session.
titled 'The collaborative role o
the
lobol tient or
onisotion communit
in advancin
En
CSEM
Ci471 orticti
ution
or univer5t71 health £overt7
e, explored how to optimise the impact of
the resolution through thoughtful and trusted cooperation and partnership at all levels.
+ Co-hosted with CSEM, UHC2030, The George Institute for Global Health, Global Health
Council, Amref, Save the Children, NCD Alliance and Global Mental Health Action Network
Iunited for Global Mental Health) on 21 May, the second event provided a platforrn for civil
society to reflect on progress and explore opportunities to Strengthen the Implementation of
the WHA77 resolution on social participation, particularly at national and regional levels.
+ With the Harvard Medical School Program in Global Primary Healthcare. UNAIDS and Gilead
Scièncès, also on 21 May. Titlèd 'A Seot at the Table, the event took the form of an art
exhibition on the importance of people-centred care as a key strategy in radi￿llY re-centring
and strengthening health Systems and primary healthcare.
+ In support of AMATA- the African Medicines Agency Treaty Alliance- and the patient saftty
agenda, we co-hosted an official side event inside the UN Palais des Nations with US
Pharmacopeia, International Pharmaceutical Student5, Federation and IFPMA on 22 Mav.
18

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Titled Addressin
the Globol Crisis o
Substandord ond Falsi
ed Medicol Products, IAPO was
one of the voice5 advocating ft)r immediate action, ernpha515ing the importance of involvin8
patients and civil society in tackling this crisis and calling for greater global attention to ensure
medicine safety and public trust in healthcare systems worldwide.
3. African Medicines Agency Treaty Alliance
Advancing.. Advocucy . Collubomtion
The Afrlcan Medlclnes A
enc
Treat Alllance
AMATA
is a multi-stakÈholder alliance set up to advocatè
for the ratification and implementation of the African Medicines Agency IAMAI Treaty and for meaningful
engagement with patients and other relevant parties in all aspect5 of the Agency framework.
In 2025 activities mainly focused on the #Afri¢anMed
NOW campaign that aims to shine 8
spotlight onAMA and its significant benefits, and put pressure on decision makers to act urgently and make
the agency a reality. The first wave of the campaign took place in February leveraging the Africa
en
19

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Union Summit to raise awareness and gather 5UPPOrters. The campaign gained strong engagement across
IAPO, AMATA. and AMATA members, on social media.
IAPO developed a '
n P k. outlining how to implement the campaign across social media
through sharing social media posts, key messages on AMA, national call to action cards, personalised
quote cards. and a launch email template. All materials were available in English. French, Portuguese, and
Arabic, ensuring accessibility 2cross Africa.
At the 75th Session of the WHO Regional Committee lor Africa in August 2025. AMATA published a
statement commendin
Member States for the
ro
ress re
orted under the Re
ional Strate
on
Re
ulation of Medical Produrts in the African Re
ion 2016-2025 (Agenda Item 16.81.
At the 78th World Health Assembly in May 2025, AMATA delivered a statement on A enda Item.. 13.5:
t ndard and Falsitied Medical Pr
du
calling on all African Member States yet to ratify the African
Medicines Agency Treaty to do so urgently. A recordin
of the statement can be viewed here.
At the 4th Conference on Public Health in Africa ICPHIA20251 held in South Africa in October 2025,
AMATA called on the African Union and all Member States to back the AMA and to recognise regulatory
system strengthening as key to a safer. healthier and MO￿ prosperous Africa. and held a side event,
ricun Medicines A
enc
..Ake
rere
uisite
oroso
er heolthier and
ros
erous A
rico" Earlier, in
lune, IAPO spoke on our AMATA work at the Africa Health Excon in EEYPt, in the session 'Advancing
Africa'5 Health Sovereignty.. Manufacturing, Regulation, and Procurement,.
4. Personalised Cancer Care Alliance {PCCA)
Advancing.. Collaboration . Empowerment
TheP
nce IPCCAI is an alliance of cancer patients, carers and representatr'ves
of patient organizations from within the WHO Eastern Mediterranean and selected countries from WHO
Africa and Europe set up to advance health literacy in cancer, advocacy skills and education on
personalised cancer care. Following a successful capacity-building workshop in late 2024 in Dubai with
patient organisations from the Gulf Cooperation Council IGCCI countries, in 2025 IAPO continued to
support the organisations that participated in the GCC and Morocco120241 workshops with information,
resources, networking and collaborations to advance personalised cancer care nationally and regionally.
A Gender Working Group IGWGI was established to craft a personalised cancer care approach that
harnesses women's distinctive insights while addressing their specific needs and challenges when
impacted by cancer.
20

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
In 2025 we co-created three new chapters of the
Eastern Mediterranean Re
ion with patient organisations of the pilots in Morocco and the GCC countries,
but also Wlth the Gender Working Group members (launched in April 20261. The Gulf and Morocco
chaptèrs highlight thÈ prattic818pplication of the 5Ps framework, whilè thÈ GWG chapter presents an
approach tailored to women's insights and needs.
We also held z workshop with the cancer patient organisations of the alliance's three streams (the
Morocco and GCC pilots, and the GWGI, on the sideline5 of our Ilth Global Patients Congress in Manila,
where we showcased progress across the streams, and together developed a roadmap to pave the way for
2026.
JJ
5. Research and evidence
Advancing.. Fucilitutlon
Unmet Patient Needs Research
In 2025. IAPO linalised the final report and three advocacy briefings as part of the Unmet Patient Needs
Research, undertaken in 2024. The survey was co-designed with IAPO members to gather valuable insights
about Ljnmet health-related needs from the perspective of patients and people with lived experience.
21

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
EOLlnPlate
We continued our support to the international research
ect EOLinPlace at the University of Coimbra,
both as part of the Patient Adviso
Gmu
and as the project's patient representative, participating in
ular adviso
and workin
rou
meetin
ro
part of our contributions to the project IAPO spoke at the EOLinPlace event 'Read
rEndo
Pla
Place
held in May in Finland. and
in
attended the EOLinPlace Annual General Meetin
held in lune in Portugal.
In September 2025, we co-hosted with the research team a consultation webinar exclusivel
IAPO members to SLJPPOrt the vzlidation of the International Classifitation of
in Plates
Common metric to classi
where
eo
le die and are cared for at the end of life which is one of the
project's rNain research deliverable5.
with
Icp
In December 2025, IAPO moderated a focus gmup with several international organisations and key
st3kÈholders with thè samè objective. The ICP was
roved in 2026 b the Unlted Nations
The BMJ Interna￿ortal pa￿ent Advlsory Panel
IAPO continued to participate as a member of The BMI Int
within the different working groups.
el, advising
In November 2025, IAPO co-authored a BMJ article titled Action is needed to implement World Hetslth
Assembly stsciolporticipotion resolutiOftJ'.
6. Stren8thenin8 our membership and community
Advancing.. Empowerment. Focilitotion
Member meetings
In 2025 we held meetings for IAPO members to strengthen our connection with them and ensure
alignment on our mission and priorities, providing opportunities for networking. relationship-building.
collaboration, and identifying new shared agendas.
22

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Patient Academy
In 2025, three new vide05 were developed for the Patient Atadem
latform on.. regulattsry affairs, sotial
pathcipation, and unmet patient needs from the patient perspective Ishowcasing the results of our
survey). IAPO members were involved in reviewing the scripts and vide05 to ensure they are meaningful
for our community.
Global pa￿entS Congress
IAPO held the Il, edition of Dur flagship event, Global Patients Con
GPC
from 16-17 November
2025. The event, held in Manila Iphilippinesl brought together our global membership alongside a diverse
range of hÈalthtare stakÈholdèrs to explorÈ key topics toncerning patients and people with livèd
experience around the world, as well a5 OPPOrtunitie5 for collaboration on shared solutions. We were
delighted to welcome almost 200 attendees to the event, both virtually and in person.
ress
The event was co-hosted with IAPO member Psoriasis Philippines IPsorPhill. and explored the theme 'From
Voices to Action.. Patient OrganisGtions ShtJping HEulth System TrGnsforrn(Ftion' across 12 inspiring
sessions. Speaker5 and moderators included patient representatives and people with lived experience, as
well as stakeholders from World Health Organization, NCD Alliance, Globalskin. Rare Diseases
International, The Synergist, Roche. Boehrineer Ingelheim, International Council of Nurses, ICHOM. and
Harvard Medical School.
Li

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Se55ion5 included an Opening Plenary from IAPO and WHO representatives, and Teodoro Javier Herbosa,
Secretary from the Department of Health. Philippines on the topic 'Why Participation in Het71th in
Non-negott'uble,. Other sessions discussed important topics such as, 'How con lived experience inform and
strengthen globol heolth commitments t7nd nutional implementotion? Turning politicol ogreements into
notional heolth strL7tegies', 'Eouity in Heolth, MokinL7 universol heolth covero9e workfor ptsrients. reol
need5, Prototyping mode15 Of cure U5ARg patient journey5. and sharing 'best pructicesfor co-creotion with
putients in health-reluted innovation,.
The event also included an open dialogue session on 'Who holrjs the power? Rebolrjncing health
ecosystems., and two Hackathon sessions on From tokenism to metsningful ptsrticipotion heolth-decision
making,.
A highlight of GPC 2025 was the launch of the Global Patient Charter on Social Partici
well-received and marked the start of the campaign to disseminate the tool worldwide.
ation which was
Additionally, on 15 November, the IAPO members, day took place with IAPO'S annual general meeting,
followed by a Learning Lab that Eathered insights from members on the UHC Compass, the Charter, and
the development of IAPO'S Regional Hubs.
Expert dialogue5
In July 2025, IAPO held a couple of dialogue5 between members and expert5 from different field5,
providing an informal environment for learning. Speakers included representatives from ICHOM and
EUPATI covering key topics for our community, including patient engagement in research and
development, value-based hezlthcare.
7. Wider partnerships and sertorcollaboration
Advoncing.. Colloboration
International Consensus Framework for Ethical Collaboration
The International Con5en5us Framework for Ethical Collaboration
ICF
was est3blished in 2014 a5 B
global platForm to ensure that relationship5 across the health ecosystem are grounded in ethical,
transparent, and responsible decision-making. It unites six leading health bodies representing patient
organisations. healthcare professionals, and the pharmaceutical industry.
On 26 June 2025, IAPO and the other five leading international organisations- representing patr'ents,
physicians IWMAI, pharmacists IFIPI, nurses IICNI, hospitals IIHFI, and the pharmaceutical industrv
24

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
IIFPMAI- adopted the first joint ethical principle in the healthcare sector on the responsible use of health
data and technology. including artr'licial intelligence.
The updated version of the ICF was launched via a jiLL0s￿l￿a%2 and an online promotional
In
campaign. Following this. IAPO sent a specific communication to members highlighting the framework's
value and encouraging them to use it.
Memberships. councils and agreements
IAPO joined Patient Focused Medicines Develo
PFMD
to represent the global patient organisation
community in this mulri-stakeholder initiative. PFMD continues to expand its scope of work and address
patient engagernent across different areas, well aligned with IAPO'S mi55i0n.
ment
IAPO joined the International Consorknum for Health Outcomes Measurements IICHOMI'S Patient Partner
Alliance.
IAPO became part of the Steering committee of the HTAI Interest Grou
Inv
in HTA
The PCIG brings together patient5 and citizens with staff from HTA bodies,
government, research, industry Ihealth technology developers) and consultancy to strengthen HTA with
the systematic incorporation of patient and citizen perspectives.
for Patient and Citizen
IAPO wa5 again invited by the International Hospitsl Federation IIHFI to serve a5 a member of the
which took place in November in Geneva.
IAPO continued to actively participate in the discussions and consultations of the
Commlsslon of which we are members, and its selected working groups.
IAPO joined the Joint Commission International'5
member.
il as a founding
Representation at external events
IAPO was 3150 represented at a number of further event5 durin8 the year..
+ the Patient Involvement Symposium hosted by the European Federation of Periodontology, held
in May in Austria.,
+ the 16th International Conference on Medical Regulation organi5ed by the International
Association of Medical Regulatory Authorities IIAMRAI, which took place in Ireland in September
2025. We presented the patient perspective to an international audience of regulators and health
25

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
professional bodies, speaking in the opening plenary 'Community Expecttstions- Whtst Reolly
MottersP';
+ the International Consorknum for Health Outcome5 Measurement Conference IICHOMI held in
Ireland at the session "Driving Change Through Potient Voices," and the ICHOM Leadership Forum,.
+ the side event organised by the Infectious Disease Alliance, titled Health Without Borders..
Integroted Primary Heolthcorefor All,: and
+ the webinar'striving for Balanced IP Systems,, which launched the IGBA report 'GamiNg the
system- An overview of originator companies evergreening strategies used to hinder access to
generic and biosimilar products,, organised by the International Generic and Biosimilar
Medicines Association IIGBAI in February.
IAPG

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Communications
IAPO maintained its newsletter subscription of over 14,000 subscribers, who receive our announcements,
campaigns 2nd regular newsletter covering all IAPO-related news 2nd updates, including initiatives such as
our congresses, mernber activitie5, advocacy news and information.
We added to the newsletter a section on relevant updates about the World Health Organization IWHOI.
including new policy documents and guidelines. important dates and advocacy campaigns. We also added
a section on upcoming events IAPO will be attending. We used several mailing campaigns to disseminate
and promote important IAPO initiative% and events throughout the year.
x Iformerly Twltter}
The IAPO secretariat continued to operate the following X accounts:
AfricanAmata
PCCAlliance.
Facebook
We Continued to operate the following Facebook accounts.. IAPOvoi
Or
anization5 Patient Solidari
Da
Personali5ed Cancer Care Alliance.
rn
tional Alli8n
of Pati
nt
Llnkedln
IAPO also continued to operate the following Linkedln account5..
Or
anizations African Medicines A
enc
Treat Alliance
AMATA
Personalised Cancer Care Alliance.
YouTube
We continued to operate IAPO'S YouTube channel-
238 videos.
IAP
which 15 currently composed of
Instagram
In November 2025 we launched an Inst3gram account
IAPO voice, connecting with as many of our
members a5 P055ible. We've currently shared 31 post5, and reached an audience of over 1,200 account5 in
the last 90 days IDec-Mar 20261
Blueskv
In December 2025 we also launched a Bluesky account
ovoice.bsk
.social.
27

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Website
www.ia
o.or
continues to be the main source of information for all IAPO'S activities, initiative5 and
events, as well as an important promotion and dissemination channel. We have spent 2025 designing and
implementing a new website. due to be launched in 2026.
UHC Compass landing paBe
www.
Sponsorship 2025
IAPO Sponsorship 2025
IAP
GSK
Roche
VIATRIS"
Gold Sponsor
Bronze Spon50r
Sponsor of initiatib*".
UHC Comp8SS
Sponsor of initiativv.
Patient Academy
Ir*•mational F*dwati¢>n
ofPharmaceuticaJ
IFPMA Manuf•ttturnrJ & Asso¢i81ion#
I Ingelheim
QMSD
Sponsor of initiatives:
Globa5 Patients Co
res& UHC
Compass. Unmet
atients
Needs research
Sponsor of initiatives:
Global Patients Congress,
AMATA
Sponsor of initiativ
Personalised Cancer
Care Alliance
28

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Membership
IAPO continued to strengthen its member network in 2025 supporting its 278 members. IAPO is currently
implementing software to streamline the entire membership management, from outreach to invoicing and
engagement. As of 31st December 2025, IAPO members were..
Region
African members
43
Eastern Mediterranean members
io
European members
96
Latin American members
67
North Arnerican member5
24
South-East Asian member
14
Western Pacific member5
24
TOTAL
278
Membershlp Type
99
Associate
37
Network
142
Affiliate
TOTAL
278
29

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Risk Management
A risk register 15 prepared by the CEO and presented annually to the Board to discuss ensuring that there
are effective and adequate risk management and internal control systems in place to manage the major
risks to which the Charity is exposed. IAPO prepares the risk register by understanding the risk
environment and its operations and then identifies the key risks. The CEO and the Treasurer then
undert8kÈ a thorough analysis and evaluation of the risks identified before coming up with a treatment for
the risks.
Risks are identifi'ed under headings of Financial, Funding, Governance, Operational and Personnel, and
mitig3tion actions detailed.
IAPO aims to diversify its funding by approaching international trust funds, international development
agencies and large programmes to raise non-industry partner funding.
Scan the QR CO
wwwJ•pfy.or8.
30

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Financial Review
Financial position at the end of the period
Incoming resources for the year amounted to £280,01712024.. £595,120), which was higher than the
previous year due to a strategic increase in research and special projects funded by our partners.
Expenditure in 2025 was £506,03412Q24.. £619.7591 Expenditure is also higher than the previous year, in
line with the fact that we increased our output in research and Special Projects.
Reserves Poliry
The IAPO Board approved a reserves policy in September 2014, with a target level of free reserves of 6-12
months. running Costs. 6 month5 fLJnning cost is c.£132,280. This polity was set with due regard to
guidance from the Charity Commission ICC19- Charity Reservesl and is reviewed annually.
The level of unrestricted reserves, as at 31st December 2025 is £213,517. This is within the target in the
reserves policy, and will be monitored by the Board of Trustees.
Going Concern
The trustees consider that there are no material uncertainties about the Charity's ability to conrinue as a
going concern. Our current partners and funders have been very receptive to new proposals and wish to
continue working with IAPO until the fo￿Seeable future.
IAPO funding transparency
The Governing Board members declare relevant conflicts of interests and conflicts of loyalty at each Board
meeting and between meetings. A register of interests is maintzined.
Reference to IAPO'S code of conduct and policy regulating IAPO's relationship with, and independence
from. sponsors can be found at www.iapo.org.uk/consensus-framework-ethical-collaboration and
www.iapo.org.uk/healthcare-industry-partners.
The overall proportion of industry to non-indu5try income for the year was approximately 99Y¢.
31

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
Pen5i0n arrangements
IAPO operates an occupational pen5i0n scheme and a150 Operate5 a policy of contribukn"on5 directly into
Staff members, chosen personal pension scheme5, Wlth no obligation for staff to make personal
contributions. The issue of pension deficit, which would apply to an occupational scheme, does not
therefore arise.
IAPQ•
32

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees. Report ft>r the Year Ended 31 December 2025
Statement of Trustees, Responsibilities
The trustees (who are also the directors of the company for the purposes of company lawl are responsible
for preparing the trustees, annual report and financial statements in accordance with applitable law and
United Kingdom Accounting Standards Iunited Kingdom Generally Accepted Accounting Practicel.
Company law requires the trustees to prepare fi'nancial statements for each financial period which give a
true and fair view of the state of affairs of the charitable company and of the incoming resources and
application of resources, including income and expenditure, of the charitable company for that period.
In preparing those financial statements, the trustees are required to..
select suitable accounting policies and then apply them consistently;
observe the methods and principles in the Charities SORP,.
make judgements and estimates that are reasonable and prudent,.
State whether applicable UK Accounting Standards have been ft)Ilowed, subject to any material
departLJres dlsclosed and explained in the financial statements- and
4 prepare the financial Statements on the going concern basis unless it 15 inappropriate to presume
that the charitable charity will continue in business.
The trustees are responsible for keeping proper accounting records, which disclose with reasonable
accuracy at any time, the h"nancial position of the charitable company and enable them to ensure that the
financial statements comply with the Companies Act 2006. They are a150 responsible for safeguarding the
assets of the charitable company and hence for taking reasonable steps for the prevention and detection
of fraud and other irregularities.
The trustees are responsible for the maintenance and integrity of the corporate and financial information
included on the charitable company's website. Legislation in the United Kingdom governing the
preparation and disseminatr'on of financial statements may differ from legislation in other jurisdictions.
Statement as to disclosure to our auditors
In so far as the trustees are aware at the dzte of approving this report..
4 there is no relevant audit information, being information needed by the auditor in connection with
preparing their report, of which the charity's auditor is unaware,. and
33

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Trustees, Report ft>r the Year Ended 31 December 2025
4 the trustees having made enquiries of fellow directors and the group's auditor that they ought to
have individually taken. have each taken all steps that helshe is obliged to take as a director in
order to make themselves aware of any relevant audit information and to establish that the auditor
is aware of that information.
Reappointment of auditors
A proposal to reappoint Knox Cropper as the charity'5 Statutory auditor5 will be put to member5 at our
forthcoming annual general meeting.
Approved and authorised for issue by the Governing Board on 15 November 2025 and signed on their
behalf by=
Professor Lara Bloom
Chair of IAPO Governing Board

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
IndependentAuditor'5 Report to the Members of International Alliance of Patients,
Organization5 for the Year Ended 31st December 2025
Opinion
We have audited the fi.nancial statements of International Alliance of Patients, Organization for the year
ended 31 December 2025 which comprise the Statement of Financial Activities (including the Income and
Expenditure Account). the Balance Sheet and the notes to the financial statements, including a summary
of signilitant accounting polities. The linancial reporting framework that has been applied in their
preparation is applicable law and United Kingdom Accounting Standards Iunited Kingdom Generally
Accepted Accounting Practice), including Financial Reporknng Stsndard 102 'The Financial Reporknng
Standard applicable in the UK and Republic of Ireland,.
In our opinion the financial statements..
4 Give a true and fair view of the state of the charitable company's affair5 as at 31 December
2025 and of it5 income and expenditure, for the period then ended;
-> Have been properly prepared in accordance with United Kingdom Generally Accepted
Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting
Standard applicable in the UK and Republic of Ireland, and
Have beèn preparèd in accordancè with the requirèments of the CompaniÈs Act 2006.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees, use of the going concern basis of
accounting in the preparation of the linancial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to
events or conditions that, individually or collectively, may cast Slgnificant doubt on the charitable
company's ability to continue as a going concern for a period of at least twelve months from when the
linancial statements are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern are described in
the relevant sections of this report.
Other information
The other informatitsn comprise5 the information included in the Trustees, Report, other than the financial
statements and our auditor'5 report thereon. The trustees are responsible for the other information.
35

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
IndependentAuditor'5 Report to the Members of International Alliance of Patients,
Organization5 for the Year Ended 31st December 2025
Our opinion on the th'nancial statements does not cover the other information and, except to the extent
otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financi31 statement5, our responsibility is to re3d the other information
and, in doing 50, consider whether the other information is materially inconsistent with the financial
statements, or our knowledge obtained in the audit or otherwise appears to be materially rllisstated. If we
identify such material inconsistencies Dr apparent material misstatements, we are required to determine
whether there is a material misstatement in the fi'nancial statements or a material misstatement of the
other information. If, based on the work we have performed, we conclude that there is 3 material
mi55tatement of thi5 Other information, we are required to report that fact. We have nothing to report in
this regard.
Opinion on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit..
The information given in the Trustees, Report, which includes the directors, report prepared
for the purp05e5 of company law, for the financial year for which the financial statements
are prepared is consistent with the financial statements,. and
The directors, report, included within the Tru5tee5' Report, h35 been prepared in accordance
with applicable legal requirernents.
Matters on which we are Required to Report by Exception
In the light of the knowledge and understanding of the charitsble company and its environment obtained
in the course of the audit. we have not identified material misstatements in the Trustees, Report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006
requires u5 to report to you if, in our opinion:
-> Adequate a¢¢ountin8 records have not been kept, or return5 adequate for our audit have
not been received from branche5 not visited by us,. or
The financial statements a￿ not in agreement with the accounting records and returns- or
4 Certain disclosures of Trustees, remuneration specified by law are not made,. or
4 We have not received all the information and explanation5 we require for our audit,. or
36

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
IndependentAuditor'5 Report to the Members of International Alliance of Patients,
Organization5 for the Year Ended 31st December 2025
The trustees were not entitled to prepare the financial statements in accordance with the
small corllpanies, regime and take advantage of the small cornpanies exemption from the
requirement to prepare a Strategic Report or in preparing the Trustees, Report.
Responslbllltles of Trustees
As explained more fully in the Statement of Trustees, Responsibilities. the trustees (who are also the
direttors of the charitable tompany for the purposes of tompany lawl are responsible for the preparation
of the linancial statement5 and for being satisfied that they give a true and fair view, and for such internal
control a5 the trustees determine is necessary to enable the preparation of financial statements that are
free from material misstatement. whether due to fraud or error.
In preparing the financial ststements, the trustees are responsible for assessing the Company's ability to
continue as a going concern, disclosing, a5 applicable, matters related to going concern and using the going
concern basis of accounting unless the trustees either intend to liquidate the company or to cease
operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are
free from material misstatement. whether due to fraud or error, and to issue an auditor's report that
includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an
audit conducted in a¢¢ordance with ISAS IUKI will always detect a material misstatement when it exists.
Mi55tatements can arise from fraud or error and are considered material if, individually or in the aggregate,
they could reasonably be expected to influence the economic decisions of users taken on the basis of
these financial statements.
Irre8ularitie5, including fraud, Bre instances of non-cornpliance with laws and regulations. We design
procedures in line with our responsibilitie5, Outlined above, to detect material misstatements in respect of
irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities,
including fraud is detailed below..
4 The Charitable Company is required to comply with both company law and charity law and,
based
4 The Charitable Company is required to comply with both company law and charity law and,
based on our knowledge of its activities, we identified that the legal requirement to
accurately account for restricted funds Wa5 of key significance.
37

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
IndependentAuditor'5 Report to the Members of International Alliance of Patients,
Organization5 for the Year Ended 31st December 2025
We gained an understanding of how the ¢haritsble Company Complied with its legal and
regulatory framework, including the requirement to properly account for restrirted funds,
through discussions with management and a review of the documented policies, procedures
and controls.
4 The audit team, which is Èxpèrièncèd in thè aLJdit of charitiès, considèred thè charitable
company's susceptibility to material misstatement and how fraLJd may occur. Our
consideration5 included the risk of management override.
Our approach was to check that all restricted income was properly identilied and separately
accounted for and to ensure that only valid and appropriate expenditure was charged to
restricted funds. This included reviewing journal adjustments and unusual transaction5.
A further description of our responsibilities for the audit of the )I'nancial statements is located on the
Financial Reporting Council's website at.. htt
www.frc.or
.uk
auditorsres
onsibilities. This description
forms part of our auditor's report.
Use of our report
This report is made solely to the charitable company's trustees. as a body. in accordance with Chapter 3 of
Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the
charitable cornp3ny'5 trustee5 those matter5 we are required to State to them in an auditors, report and for
no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to
anyone other than the charitable company and the charitable company's trustees as a body, for our audit
work, for this report, or for the opinions we have formed.
Liv Burrell (Senior Statutory Auditor)
For and on behalf of Knox Cropper LLP (Statutory Auditor)
65 Le8denh811 Street
London
EC3A 2AD
2810812026
38

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Statement of Financial Activities (incorporating an income and expenditure account) for the
Year Ended 31 December 2025
Total
2025
Total
2024
t Unrestrlcted
De$lgn•ted
Re$trl¢ted
(year)
(year)
Income from charitable
activities:
Nembership
Healthcare Industry Partners
APPC congress
GPC congress
Special Project5
Other charitable activitie5
193
81,336
51,867
51,867
64,762
64,762
145,208
18,180
145,208
488,499
25,092
18,180
Total
70.047
64,762
145.208
280.017
595.120
Expenditure on charitable
Activities:
Charitable artivitles..
Capacity building. advocacy
and collaboration
Asia Pacific Patients Congress
197,0941
197,0941
197,2061
Global Patients Congress
186,0081
186,0081
Special projects
1322,9321
1322,9321
1522,5531
Total
(97.094)
(86.008)
{322.932) (506,034) (619,759)
Net Income/(expendlture)
(27,047)
(21,246)
{177,724) (226,017)
(24,639)
Transfers
Net movement In funds
127,0471
121,2461
1177,7241
1226,0171
124,6391
Reconciliation of funds:
Funds brought forward
240.564
(21.351)
301.390
520.603
545.242
Total funds carried forward
213,517
(42,597)
123,666
294,586
520,603
All transactions are derived from continuing activities.
All recognised gains and losses are included in the Statement of Financial Activities.
39

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Balance Sheet as at 31 December 2025
Notes
2025
2024
Fixed assets
Current assets
Debtors
Cash in hand and in bank
23,583
281,016
56,885
507,451
304,599
564,336
Creditors: amounts falling due within one year
(10,013)
143,7331
Net current asset$
294,586
520,603
Net assets
294,586
520,603
Funds
Unrestricted Funds
Designated Funds
Restricted Funds
213,517
142,597)
123,666
240,564
121,3511
301,390
Total Funds
294,586
520,603
These financial statements have been prepared in accordance with the special provisions of Part 15 of
the Companies Act 2006 relating to small charitsble companies.
These flnanclal statements were approved and authorlsed for Issue by the Governlng Board on
L l August 2026 and signed on their behalf by..
Professor Lara Bloom
Ms. Flavia Kyomukama
Chair
Treasurer
Reglstered company number.. 0849571 L (England and Wales)
The notes on pages 41 to 51 form part of these financial statements.
40

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statements for the Year Ended 31 Detember 2025
4 Governance costs include those costs associated with meeting the constitutional and
statutory requirements of the charity and include the audit fees and costs linked to th
strategic management of the charity.
All costs are allocated between expenditure categories of the SOFA on a basis designed to
reflect the use of the resource. Costs relating to a particular activity are allocated directly,
other costs are apportioned on the basis staff time incurred.
The core elements of charitable expenditure are as follows..
Capacity Building: Realising active partnerships with patients, orEanisations, maximising their impact
through capacity building.
Advotaty.. Advocating internationally with a strong patients, voice on the relevant aspetts of healthcare
policy. with the aim of influencing international. regional and national health agendas and policie5.
Collaboration- Building cross-sertor alliance and working collabor2tively with like-minded medical and
health professionals, policy makers, academics, researchers and industry representatives.
1.5 Funds
General funds are unrestricted funds which are available for use at the discretion of the Trustees in
furtherance of the general objectives of the charity and which have not been designated for other
purposes.
Designated funds are funds which are'ring-fenced, to be used for the specific purpose of the congre55.
Restricted funds are funds, which are to be used in accordance with specific restrictions imposed by the
donor. The aim and use of the restricted fund 15 Set out in the notes of the financial statements.
1.6 Tangible fixed a55et5 and depreciation
Capital expenditure on items costing £1,000 or higher are recorded as tangible fi'xed assets. Tangible fixed
assets are stated at historical cost less dep￿CiatiOn.
Depreciation is provided to reflert the useful estimated economic life of computer equipment assets at a
rate of 33°A per annum (reducing balance method).
41

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
l. Incoming re50urce5
Healthcare
Industry
Partners
OTHER
Projects
Total
GSK
37,204
14,663
37.204
14,663
145,208
82.942
Roche
Projects
Other income
145,208
82,942
82,942
51,867
145,208
280,017
Income Resources comparatiTve 2024
Healthcare
Industry
Partners
OTHER
Projects
Total
IFPMA
43,113
38,223
43,113
38,223
488,499
25,285
GSK
Projerts
other income
488,499
25,285
25,285
81,336
488,499
595,120
42

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
2. Congre55 Support 2025
APPC congress
GPC congress
Total
PAPO
Boehringer Ingelheim
TFPMA
Online Transattions
19,988
21,265
13,675
9,834
19,988
21,265
13,675
9,834
64,762
64,762
Congress Support 2024
APPC congress
GPC congress
Total
There was no congress held in 2024 but IAPO is holding the GPC in November 2025 in
the Philippine5.
43

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
3. Expenditure on Charitable Activities
Staff Costs
Other Costs
Support
Costs
Total
Capacity Building1 advocacy
and collaboration
38,792
58,301
97,093
Congress
9,684
76,325
86,008
Speclal Projects
87,152
148,328
87,452
322,932
Total
135,628
224,653
145,753
506,034
Expenditure on Charitable Activities Comparative
Staff Costs
Other Costs
Support
Costs
Totsl
Capacity Buildingi advocacy
and collaboration
22,870
74,113
96,983
Congress
Special Projects
86,235
325,757
110,784
522,776
Total
109, 105
325,757
184,897
619,759
4. Analysis of support costs
Capacity
BuSldlngi
advocacy and
collaboration
Congress
SpecSal
Projects
Total
Rent and Rates
420
630
1,050
other Office Costs
Legal and Professlonal
Fees
14,485
21,728
36,213
40,180
60,270
100,450
Audit Fees
3,216
4,824
8.040
Total
58,301
87,452
145,753
640/0 of the charity'5 total resources including activities, staff time, and professional expert15e -were
dedicated to supporting our projects and ensuring the achievement of our deliverables.
44

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
Analysis of support COSt5 comparative
Capacity Building
advocacy and
collaboration
Congress
Special
Projects
Total
Rent and Rates
3,000
4,500
7,500
Other offi￿ Costs
30,149
44,839
74,988
LÈgal and Professional Féés
35,772
53,657
89,429
Audit Fees
5, 192
7,788
12,980
Total
74,113
110,784
184,897
45

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
5. Tru5tee5 and staff remuneration
The trustees received no ￿muneration. The Charity also paid £8,506 on behalf of Trustees to allow them
to ftjlfil their duties (2024.. £25,373).
staff rèmuneratiTon and numbers
Total
2025
Total
2024
Wages and salaries
Social Security
Pension costs
126,346
6,613
2,670
125,376
13,167
660
135,628
139.203
The average number of full and part-time employee5 during the year was 3. 1 individual employee
received emoluments in excess of £60,00012024.. 1 in the band £60,001 to £70,000). Key management
personnel costs amounted to £66,391 {2024.. £66.391).
46

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
6. Operating Surplus
Operating surplus is stated after charging.
Total
2025
Total
2024
Auditors Remuneration
Depreciation of Assets
Operating Lease Charges (office rental)
7,320
5,550
7,500
7. Fixed Assets
Computer
equipmént
Cost
Brought forward
4,169
Carried forward
Depreciation
Brought forward
Charge for the year
4,169
CarrSed forward
Net book value
At 31 December 2024
At 31 December 2023
There are no charges or securltles held over any fixed assets. All fixed assets are held In the charity and
none in the trading subsidiary. Depreciation was nil was in the previous period.
47

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
8. Debtors
2025
2024
Debtors
Prepayments
Accrued income
50,000
6,885
23,583
23,583
56,885
9. Creditors: amount falling due within one year
2025
2024
Creditors
Deferred income
Accruals
288
21,512
22,221
9,725
10.013
43,733
10. Analysis of net assets between funds
Unrestricted
Fund
Designated Restricted
Funds
Funds
Total Funds
Current assets
Current liabilities
223,530
110,0131
142,5971
123,666
304,599
(10,013)
As at 31 December 2025
213,517
142,5971
123,666
294.586
48

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
Analysis of net assets between funds compardtive
Unrestricted
Fund
Designated Restricted
Funds
Fund5
Total Fund5
Current assets
Current liabilities
262,946
(22,3821
301,390
564.336
(43,733)
121,3511
As at 31 December 2024
240,564
121,3511
301,390
520.603
The deficit in the designated fund is primarily due to the extra staff costs asSOClated with covering these
events that we did not get funding for In the past.
11. Movement in funds 2025
At31
December
2024
Incoming
Resources
Resources
Expended
At31
December
2025
Transfers
Unrestricted fund
240,564
70,047
(97,0941
213,517
esi
nat
APPC congress
33,978
33,978
GPC congress
Africa congress
Latln Congress
(9,6171
122,241)
123,4711
64,762
(86,0081
(30,863)
(22.241)
(23,471)
Special projects
301,390
145,208
1322,9321
123,666
520,603
280.017
{506.034)
294.586
49

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
Movements in funds comparative
Al31
December
2023
Lncorning
Resources
Resources
Expended
At31
December
2024
Transfers
231,149
106,621
(97,2061
240,564
Desi
nated Fund5'.
APPC congress
GPC congress
Africa congress
Latin Congress
33,978
19,6171
122,2411
123,4711
33,978
(9,617)
(22.241)
(23,471)
Special projert5
335,444
488,499
1522,5531
301,390
545,242
595, 120
1619,7591
520.603
so

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
12. SOFA- Comparative
Totsl
2024
Unrestricted
Designated
Restricted
(year)
Income from charitable
activities:
Nembership
Healthcare Industry Partners
APPC congress
GPC congress
Special Projects
Other charitable activities
193
81,336
193
81,336
488,499
488,499
25,092
25,092
Total
106.621
488,499
595,120
Expenditure on charitable
Activities:
Charitable activities'.-
Capacity building. advocacy and
collaboration
197,2061
197,2061
Asia Pacific Patients Congress
Global Patients Congress
Special projects
{522,5531
1522,5531
Total
(97,206)
(522.553)
{619,759)
Net Income/(expendlture)
9,415
(34,054)
(24,639)
Trnnsfe
Net movement in funds
9,415
134.0541
124,6391
Reconciliation of funds:
Funds brought forward
231.149
(21,351)
335.444
545.242
Total funds carrled forward
240,564
(21,351)
301,390
520.603
Related Party Transactions
There were no related party transactlons other than relmbursement of Trustee expenses as detalled In
Note 6 12023.. nil)
si

IAPO
of
Thank ou
The Intemational of Patients, Or8￿1zati￿5 is re&wtered in England and
Wales as chwityn. n55577 and cO￿vanY knmted by 8uarwrtge n. 084957n
Q Adckess Caropl 82 street Lorthry SEI 3GN L
Websita WWtrvw¢xofgA*

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
IndependentAuditor'5 Report to the Members of International Alliance of Patients,
Organization5 for the Year Ended 31st December 2025
Opinion
We have audited the fi.nancial statements of International Alliance of Patients, Organization for the year
ended 31 December 2025 which comprise the Statement of Financial Activities (including the Income and
Expenditure Account). the Balance Sheet and the notes to the financial statements, including a summary
of signilitant accounting polities. The linancial reporting framework that has been applied in their
preparation is applicable law and United Kingdom Accounting Standards Iunited Kingdom Generally
Accepted Accounting Practice), including Financial Reporknng Stsndard 102 'The Financial Reporknng
Standard applicable in the UK and Republic of Ireland,.
In our opinion the financial statements..
4 Give a true and fair view of the state of the charitable company's affair5 as at 31 December
2025 and of it5 income and expenditure, for the period then ended;
-> Have been properly prepared in accordance with United Kingdom Generally Accepted
Accounting Practice, including Financial Reporting Standard 102 'The Financial Reporting
Standard applicable in the UK and Republic of Ireland, and
Have beèn preparèd in accordancè with the requirèments of the CompaniÈs Act 2006.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the trustees, use of the going concern basis of
accounting in the preparation of the linancial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to
events or conditions that, individually or collectively, may cast Slgnificant doubt on the charitable
company's ability to continue as a going concern for a period of at least twelve months from when the
linancial statements are authorised for issue.
Our responsibilities and the responsibilities of the trustees with respect to going concern are described in
the relevant sections of this report.
Other information
The other informatitsn comprise5 the information included in the Trustees, Report, other than the financial
statements and our auditor'5 report thereon. The trustees are responsible for the other information.
35

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
IndependentAuditor'5 Report to the Members of International Alliance of Patients,
Organization5 for the Year Ended 31st December 2025
Our opinion on the th'nancial statements does not cover the other information and, except to the extent
otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
In connection with our audit of the financi31 statement5, our responsibility is to re3d the other information
and, in doing 50, consider whether the other information is materially inconsistent with the financial
statements, or our knowledge obtained in the audit or otherwise appears to be materially rllisstated. If we
identify such material inconsistencies Dr apparent material misstatements, we are required to determine
whether there is a material misstatement in the fi'nancial statements or a material misstatement of the
other information. If, based on the work we have performed, we conclude that there is 3 material
mi55tatement of thi5 Other information, we are required to report that fact. We have nothing to report in
this regard.
Opinion on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit..
The information given in the Trustees, Report, which includes the directors, report prepared
for the purp05e5 of company law, for the financial year for which the financial statements
are prepared is consistent with the financial statements,. and
The directors, report, included within the Tru5tee5' Report, h35 been prepared in accordance
with applicable legal requirernents.
Matters on which we are Required to Report by Exception
In the light of the knowledge and understanding of the charitsble company and its environment obtained
in the course of the audit. we have not identified material misstatements in the Trustees, Report.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006
requires u5 to report to you if, in our opinion:
-> Adequate a¢¢ountin8 records have not been kept, or return5 adequate for our audit have
not been received from branche5 not visited by us,. or
The financial statements a￿ not in agreement with the accounting records and returns- or
4 Certain disclosures of Trustees, remuneration specified by law are not made,. or
4 We have not received all the information and explanation5 we require for our audit,. or
36

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
IndependentAuditor'5 Report to the Members of International Alliance of Patients,
Organization5 for the Year Ended 31st December 2025
The trustees were not entitled to prepare the financial statements in accordance with the
small corllpanies, regime and take advantage of the small cornpanies exemption from the
requirement to prepare a Strategic Report or in preparing the Trustees, Report.
Responslbllltles of Trustees
As explained more fully in the Statement of Trustees, Responsibilities. the trustees (who are also the
direttors of the charitable tompany for the purposes of tompany lawl are responsible for the preparation
of the linancial statement5 and for being satisfied that they give a true and fair view, and for such internal
control a5 the trustees determine is necessary to enable the preparation of financial statements that are
free from material misstatement. whether due to fraud or error.
In preparing the financial ststements, the trustees are responsible for assessing the Company's ability to
continue as a going concern, disclosing, a5 applicable, matters related to going concern and using the going
concern basis of accounting unless the trustees either intend to liquidate the company or to cease
operations, or have no realistic alternative but to do so.
Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are
free from material misstatement. whether due to fraud or error, and to issue an auditor's report that
includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an
audit conducted in a¢¢ordance with ISAS IUKI will always detect a material misstatement when it exists.
Mi55tatements can arise from fraud or error and are considered material if, individually or in the aggregate,
they could reasonably be expected to influence the economic decisions of users taken on the basis of
these financial statements.
Irre8ularitie5, including fraud, Bre instances of non-cornpliance with laws and regulations. We design
procedures in line with our responsibilitie5, Outlined above, to detect material misstatements in respect of
irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities,
including fraud is detailed below..
4 The Charitable Company is required to comply with both company law and charity law and,
based
4 The Charitable Company is required to comply with both company law and charity law and,
based on our knowledge of its activities, we identified that the legal requirement to
accurately account for restricted funds Wa5 of key significance.
37

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
IndependentAuditor'5 Report to the Members of International Alliance of Patients,
Organization5 for the Year Ended 31st December 2025
We gained an understanding of how the ¢haritsble Company Complied with its legal and
regulatory framework, including the requirement to properly account for restrirted funds,
through discussions with management and a review of the documented policies, procedures
and controls.
4 The audit team, which is Èxpèrièncèd in thè aLJdit of charitiès, considèred thè charitable
company's susceptibility to material misstatement and how fraLJd may occur. Our
consideration5 included the risk of management override.
Our approach was to check that all restricted income was properly identilied and separately
accounted for and to ensure that only valid and appropriate expenditure was charged to
restricted funds. This included reviewing journal adjustments and unusual transaction5.
A further description of our responsibilities for the audit of the )I'nancial statements is located on the
Financial Reporting Council's website at.. htt
www.frc.or
.uk
auditorsres
onsibilities. This description
forms part of our auditor's report.
Use of our report
This report is made solely to the charitable company's trustees. as a body. in accordance with Chapter 3 of
Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the
charitable cornp3ny'5 trustee5 those matter5 we are required to State to them in an auditors, report and for
no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to
anyone other than the charitable company and the charitable company's trustees as a body, for our audit
work, for this report, or for the opinions we have formed.
Liv Burrell (Senior Statutory Auditor)
For and on behalf of Knox Cropper LLP (Statutory Auditor)
65 Le8denh811 Street
London
EC3A 2AD
2810812026
38

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Statement of Financial Activities (incorporating an income and expenditure account) for the
Year Ended 31 December 2025
Total
2025
Total
2024
t Unrestrlcted
De$lgn•ted
Re$trl¢ted
(year)
(year)
Income from charitable
activities:
Nembership
Healthcare Industry Partners
APPC congress
GPC congress
Special Project5
Other charitable activitie5
193
81,336
51,867
51,867
64,762
64,762
145,208
18,180
145,208
488,499
25,092
18,180
Total
70.047
64,762
145.208
280.017
595.120
Expenditure on charitable
Activities:
Charitable artivitles..
Capacity building. advocacy
and collaboration
Asia Pacific Patients Congress
197,0941
197,0941
197,2061
Global Patients Congress
186,0081
186,0081
Special projects
1322,9321
1322,9321
1522,5531
Total
(97.094)
(86.008)
{322.932) (506,034) (619,759)
Net Income/(expendlture)
(27,047)
(21,246)
{177,724) (226,017)
(24,639)
Transfers
Net movement In funds
127,0471
121,2461
1177,7241
1226,0171
124,6391
Reconciliation of funds:
Funds brought forward
240.564
(21.351)
301.390
520.603
545.242
Total funds carried forward
213,517
(42,597)
123,666
294,586
520,603
All transactions are derived from continuing activities.
All recognised gains and losses are included in the Statement of Financial Activities.
39

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Balance Sheet as at 31 December 2025
Notes
2025
2024
Fixed assets
Current assets
Debtors
Cash in hand and in bank
23,583
281,016
56,885
507,451
304,599
564,336
Creditors: amounts falling due within one year
(10,013)
143,7331
Net current asset$
294,586
520,603
Net assets
294,586
520,603
Funds
Unrestricted Funds
Designated Funds
Restricted Funds
213,517
142,597)
123,666
240,564
121,3511
301,390
Total Funds
294,586
520,603
These financial statements have been prepared in accordance with the special provisions of Part 15 of
the Companies Act 2006 relating to small charitsble companies.
These flnanclal statements were approved and authorlsed for Issue by the Governlng Board on
L l August 2026 and signed on their behalf by..
Professor Lara Bloom
Ms. Flavia Kyomukama
Chair
Treasurer
Reglstered company number.. 0849571 L (England and Wales)
The notes on pages 41 to 51 form part of these financial statements.
40

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statements for the Year Ended 31 Detember 2025
4 Governance costs include those costs associated with meeting the constitutional and
statutory requirements of the charity and include the audit fees and costs linked to th
strategic management of the charity.
All costs are allocated between expenditure categories of the SOFA on a basis designed to
reflect the use of the resource. Costs relating to a particular activity are allocated directly,
other costs are apportioned on the basis staff time incurred.
The core elements of charitable expenditure are as follows..
Capacity Building: Realising active partnerships with patients, orEanisations, maximising their impact
through capacity building.
Advotaty.. Advocating internationally with a strong patients, voice on the relevant aspetts of healthcare
policy. with the aim of influencing international. regional and national health agendas and policie5.
Collaboration- Building cross-sertor alliance and working collabor2tively with like-minded medical and
health professionals, policy makers, academics, researchers and industry representatives.
1.5 Funds
General funds are unrestricted funds which are available for use at the discretion of the Trustees in
furtherance of the general objectives of the charity and which have not been designated for other
purposes.
Designated funds are funds which are'ring-fenced, to be used for the specific purpose of the congre55.
Restricted funds are funds, which are to be used in accordance with specific restrictions imposed by the
donor. The aim and use of the restricted fund 15 Set out in the notes of the financial statements.
1.6 Tangible fixed a55et5 and depreciation
Capital expenditure on items costing £1,000 or higher are recorded as tangible fi'xed assets. Tangible fixed
assets are stated at historical cost less dep￿CiatiOn.
Depreciation is provided to reflert the useful estimated economic life of computer equipment assets at a
rate of 33°A per annum (reducing balance method).
41

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
l. Incoming re50urce5
Healthcare
Industry
Partners
OTHER
Projects
Total
GSK
37,204
14,663
37.204
14,663
145,208
82.942
Roche
Projects
Other income
145,208
82,942
82,942
51,867
145,208
280,017
Income Resources comparatiTve 2024
Healthcare
Industry
Partners
OTHER
Projects
Total
IFPMA
43,113
38,223
43,113
38,223
488,499
25,285
GSK
Projerts
other income
488,499
25,285
25,285
81,336
488,499
595,120
42

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
2. Congre55 Support 2025
APPC congress
GPC congress
Total
PAPO
Boehringer Ingelheim
TFPMA
Online Transattions
19,988
21,265
13,675
9,834
19,988
21,265
13,675
9,834
64,762
64,762
Congress Support 2024
APPC congress
GPC congress
Total
There was no congress held in 2024 but IAPO is holding the GPC in November 2025 in
the Philippine5.
43

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
3. Expenditure on Charitable Activities
Staff Costs
Other Costs
Support
Costs
Total
Capacity Building1 advocacy
and collaboration
38,792
58,301
97,093
Congress
9,684
76,325
86,008
Speclal Projects
87,152
148,328
87,452
322,932
Total
135,628
224,653
145,753
506,034
Expenditure on Charitable Activities Comparative
Staff Costs
Other Costs
Support
Costs
Totsl
Capacity Buildingi advocacy
and collaboration
22,870
74,113
96,983
Congress
Special Projects
86,235
325,757
110,784
522,776
Total
109, 105
325,757
184,897
619,759
4. Analysis of support costs
Capacity
BuSldlngi
advocacy and
collaboration
Congress
SpecSal
Projects
Total
Rent and Rates
420
630
1,050
other Office Costs
Legal and Professlonal
Fees
14,485
21,728
36,213
40,180
60,270
100,450
Audit Fees
3,216
4,824
8.040
Total
58,301
87,452
145,753
640/0 of the charity'5 total resources including activities, staff time, and professional expert15e -were
dedicated to supporting our projects and ensuring the achievement of our deliverables.
44

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
Analysis of support COSt5 comparative
Capacity Building
advocacy and
collaboration
Congress
Special
Projects
Total
Rent and Rates
3,000
4,500
7,500
Other offi￿ Costs
30,149
44,839
74,988
LÈgal and Professional Féés
35,772
53,657
89,429
Audit Fees
5, 192
7,788
12,980
Total
74,113
110,784
184,897
45

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
5. Tru5tee5 and staff remuneration
The trustees received no ￿muneration. The Charity also paid £8,506 on behalf of Trustees to allow them
to ftjlfil their duties (2024.. £25,373).
staff rèmuneratiTon and numbers
Total
2025
Total
2024
Wages and salaries
Social Security
Pension costs
126,346
6,613
2,670
125,376
13,167
660
135,628
139.203
The average number of full and part-time employee5 during the year was 3. 1 individual employee
received emoluments in excess of £60,00012024.. 1 in the band £60,001 to £70,000). Key management
personnel costs amounted to £66,391 {2024.. £66.391).
46

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
6. Operating Surplus
Operating surplus is stated after charging.
Total
2025
Total
2024
Auditors Remuneration
Depreciation of Assets
Operating Lease Charges (office rental)
7,320
5,550
7,500
7. Fixed Assets
Computer
equipmént
Cost
Brought forward
4,169
Carried forward
Depreciation
Brought forward
Charge for the year
4,169
CarrSed forward
Net book value
At 31 December 2024
At 31 December 2023
There are no charges or securltles held over any fixed assets. All fixed assets are held In the charity and
none in the trading subsidiary. Depreciation was nil was in the previous period.
47

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
8. Debtors
2025
2024
Debtors
Prepayments
Accrued income
50,000
6,885
23,583
23,583
56,885
9. Creditors: amount falling due within one year
2025
2024
Creditors
Deferred income
Accruals
288
21,512
22,221
9,725
10.013
43,733
10. Analysis of net assets between funds
Unrestricted
Fund
Designated Restricted
Funds
Funds
Total Funds
Current assets
Current liabilities
223,530
110,0131
142,5971
123,666
304,599
(10,013)
As at 31 December 2025
213,517
142,5971
123,666
294.586
48

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
Analysis of net assets between funds compardtive
Unrestricted
Fund
Designated Restricted
Funds
Fund5
Total Fund5
Current assets
Current liabilities
262,946
(22,3821
301,390
564.336
(43,733)
121,3511
As at 31 December 2024
240,564
121,3511
301,390
520.603
The deficit in the designated fund is primarily due to the extra staff costs asSOClated with covering these
events that we did not get funding for In the past.
11. Movement in funds 2025
At31
December
2024
Incoming
Resources
Resources
Expended
At31
December
2025
Transfers
Unrestricted fund
240,564
70,047
(97,0941
213,517
esi
nat
APPC congress
33,978
33,978
GPC congress
Africa congress
Latln Congress
(9,6171
122,241)
123,4711
64,762
(86,0081
(30,863)
(22.241)
(23,471)
Special projects
301,390
145,208
1322,9321
123,666
520,603
280.017
{506.034)
294.586
49

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
Movements in funds comparative
Al31
December
2023
Lncorning
Resources
Resources
Expended
At31
December
2024
Transfers
231,149
106,621
(97,2061
240,564
Desi
nated Fund5'.
APPC congress
GPC congress
Africa congress
Latin Congress
33,978
19,6171
122,2411
123,4711
33,978
(9,617)
(22.241)
(23,471)
Special projert5
335,444
488,499
1522,5531
301,390
545,242
595, 120
1619,7591
520.603
so

IAP
Intemafjonal Alllance of Pafjent5' Organlzafjons
Notes to the Financial Statement5 for the Year Ended 31 December 2025
12. SOFA- Comparative
Totsl
2024
Unrestricted
Designated
Restricted
(year)
Income from charitable
activities:
Nembership
Healthcare Industry Partners
APPC congress
GPC congress
Special Projects
Other charitable activities
193
81,336
193
81,336
488,499
488,499
25,092
25,092
Total
106.621
488,499
595,120
Expenditure on charitable
Activities:
Charitable activities'.-
Capacity building. advocacy and
collaboration
197,2061
197,2061
Asia Pacific Patients Congress
Global Patients Congress
Special projects
{522,5531
1522,5531
Total
(97,206)
(522.553)
{619,759)
Net Income/(expendlture)
9,415
(34,054)
(24,639)
Trnnsfe
Net movement in funds
9,415
134.0541
124,6391
Reconciliation of funds:
Funds brought forward
231.149
(21,351)
335.444
545.242
Total funds carrled forward
240,564
(21,351)
301,390
520.603
Related Party Transactions
There were no related party transactlons other than relmbursement of Trustee expenses as detalled In
Note 6 12023.. nil)
si

IAPO
of
Thank ou
The Intemational of Patients, Or8￿1zati￿5 is re&wtered in England and
Wales as chwityn. n55577 and cO￿vanY knmted by 8uarwrtge n. 084957n
Q Adckess Caropl 82 street Lorthry SEI 3GN L
Websita WWtrvw¢xofgA*